Cutler Group LP Bei Gene, Ltd. Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$125.51 - $229.3 $89,614 - $163,720	714 New	714 $157,000
Q2 2022 Aug 04, 2022	SELL	$121.11 - $216.05 $1,211 - $2,160	-10 Reduced 20.0%	40 $6,000
Q1 2022 Apr 14, 2022	SELL	$146.52 - $269.56 $219,780 - $404,340	-1,500 Reduced 96.77%	50 $9,000
Q4 2020 Jan 21, 2021	BUY	$221.31 - $316.61 $276,637 - $395,762	1,250 Added 416.67%	1,550 $400,000
Q3 2020 Oct 27, 2020	SELL	$189.18 - $286.44 $590,809 - $894,552	-3,123 Reduced 91.24%	300 $85,000
Q1 2020 May 07, 2020	BUY	$121.84 - $173.19 $112,702 - $160,200	925 Added 37.03%	3,423 $421,000
Q4 2019 Feb 06, 2020	BUY	$115.78 - $208.34 $197,057 - $354,594	1,702 Added 213.82%	2,498 $414,000
Q3 2019 Oct 28, 2019	SELL	$120.61 - $148.29 $193,458 - $237,857	-1,604 Reduced 66.83%	796 $97,000
Q1 2019 May 10, 2019	BUY	$122.82 - $151.83 $73,692 - $91,098	600 Added 33.33%	2,400 $316,000
Q4 2018 Feb 05, 2019	BUY	$107.01 - $175.15 $40,984 - $67,082	383 Added 27.03%	1,800 $252,000
Q2 2018 Aug 10, 2018	BUY	$152.5 - $216.77 $216,092 - $307,163	1,417 New	1,417 $217,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.